Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Company profile
Ticker
ONCO
Exchange
Website
CEO
Dr. Ralph Schiess Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Blue Water Biotech, Inc., Blue Water Vaccines Inc.
SEC CIK
Corporate docs
Subsidiaries
Proteomedix AG ...
ONCO stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Sep 24
8-K
Entry into a Material Definitive Agreement
20 Sep 24
8-K
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders
20 Sep 24
8-K
Submission of Matters to a Vote of Security Holders
10 Sep 24
8-K
Other Events
4 Sep 24
DEFA14A
Additional proxy soliciting materials
3 Sep 24
8-K
Other Events
3 Sep 24
10-Q
2024 Q2
Quarterly report
29 Aug 24
NT 10-Q
Notice of late quarterly filing
14 Aug 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
7 Aug 24
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 930.54 k | 930.54 k | 930.54 k | 930.54 k | 930.54 k | 930.54 k |
Cash burn (monthly) | 1.18 mm | 691.01 k | 4.75 mm | 4.34 mm | 1.07 mm | 1.32 mm |
Cash used (since last report) | 3.44 mm | 2.02 mm | 13.89 mm | 12.67 mm | 3.12 mm | 3.84 mm |
Cash remaining | -2.51 mm | -1.09 mm | -12.96 mm | -11.74 mm | -2.19 mm | -2.91 mm |
Runway (months of cash) | -2.1 | -1.6 | -2.7 | -2.7 | -2.1 | -2.2 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 14 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 216.04 mm |
Total shares | 4.53 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AFG American Financial | 1.44 mm | $241.00 k |
Altos Venture | 1.10 mm | $0.00 |
Cincytech Fund Iv | 832.84 k | $41.48 mm |
Zurcher Kantonalbank | 306.08 k | $51.18 mm |
BAC Bank of America | 125.13 k | $20.90 mm |
Susquehanna International | 113.68 k | $19.01 mm |
HRT Financial | 104.59 k | $17.00 k |
FITB Fifth Third Bancorp | 96.20 k | $16.08 mm |
Geode Capital Management | 95.26 k | $15.93 mm |
Jane Street | 87.03 k | $14.55 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Sep 24 | Christian Bruhlmann | Common Stock | Grant | Acquire A | No | No | 0 | 428,010 | 0.00 | 433,910 |
24 Sep 24 | Ralph Schiess | Common Stock | Grant | Acquire A | No | No | 0 | 489,160 | 0.00 | 0 |
News
Dow Surges Over 100 Points; Costco Earnings Top Views
27 Sep 24
Market-Moving News for September 27th
27 Sep 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
27 Sep 24
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
27 Sep 24
Why Onconetix (ONCO) Shares Are Down 27%
20 Sep 24